Home at last!

[Catdancer]

Yeah, I am using my kindle for nearly everything too. Haven't so much as opened my laptop in the 7 weeks I've been "away". Now that I'm home, I find that my printer is broke....some message about "Printheads are misaligned please reinstall ink cartridges" which I did without success, but haven't had time to do much more troubleshooting. Need to fix that, but I can even print from my kindle. It took me awhile, but I can type pretty quickly on here with just one finger. I wouldn't want to type a whole letter, but for this, it works great. I shop on here, search, Facebook, play games, most everything I do on a laptop..

[jendie]

I don't know how I missed this official, back to BT post from you, Cat, but welcome back!

[Howie]

Jendie, go stand in the corner!

[jendie]

Jendie, go stand in the corner!

I can't stand for more than 10 minutes, so I'll sit in the corner... and I'll bring my laptop with me.

[Sunshine]

You are amazing! i am so glad you chose to fight this thing and that you prevailed! Welcome home :)

[SuzE-Q]

Cat,

I wonder if this might be something to consider if you're still troubled by bladder issues?

Only registered and activated users can see links., Click Here To Register...

Neurourol Urodyn.

2015 Dec 29.
doi: 10.1002/nau.22945. [Epub ahead of print]

Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study.

Amarenco G1, Sutory M2, Zachoval R3, Agarwal M4, Del Popolo G5, Tretter R6, Compion G7, De Ridder D8.

Abstract
AIMS:
To investigate the effect on urodynamics of 4 weeks treatment with solifenacin succinate in patients with neurogenic detrusor overactivity (NDO) due to multiple sclerosis (MS) or spinal cord injury (SCI).

METHODS:
SONIC was a prospective, multicenter, double-blind, phase 3b/4 study investigating the efficacy and safety of solifenacin 10 mg in patients with NDO due to MS or SCI. Patients (n = 189) were randomized to placebo or active treatment (solifenacin 5 mg, 10 mg or oxybutynin hydrochloride 15 mg) for 4 weeks, after a 2-week, single-blind, placebo run-in period.

The primary endpoint was change in maximum cystometric capacity (MCC) from baseline to end of treatment. The primary analysis compared solifenacin 10 mg versus placebo; all other comparisons were considered secondary. Secondary endpoints included changes in urodynamic parameters, patient-reported outcomes, and safety assessments.

RESULTS:
In the primary analysis, solifenacin 10 mg significantly improved mean change from baseline MCC versus placebo (P < 0.001) and was associated with improvements in bladder volume at first contraction and at first leak as well as detrusor pressure at first leak.

Similar results were obtained for oxybutynin versus placebo. Patient perception of bladder condition significantly improved with solifenacin 10 mg versus placebo (P = 0.041). There was a clear improvement in quality of life (QoL) in the solifenacin arms versus placebo. The overall incidence of adverse events was low.

CONCLUSIONS:
In patients with NDO due to MS and SCI, 4 weeks of treatment with solifenacin 10 mg improved urodynamic variables and QoL versus placebo and was well tolerated